Ocumension Therapeutics Environmental Analytics
Environmental and financial analysis dashboard for Ocumension Therapeutics. Industry: MANUFACTURING
Company Overview for Ocumension Therapeutics
Highlights
Showing data for FY2022
Operational Environmental Cost
$1.62m
Operational Environmental Cost Intensity
7.07%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$1.59m
Decoupling Rate (2020-2022)
-144%
Adjusted EBITDA
$-53m
Adjusted EBITDA Margin
-234%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 7.00% | 10065.66% | -60.73% | ||
| 0.21% | 0.05% | 1.96% | 0.51% | |
| 188.08% | 1966.24% | -8.94% | ||
| 0.98% | 0.64% | 5.11% | 3.06% | |
| $0m | $0m | $2m | $1m | |
| 156.69% | 2551.45% | -23.28% | ||
| 1.19% | 0.69% | 7.07% | 3.57% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-234%
Adjusted EBIT Margin
-259%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$2m | $9m | $23m | $35m | |
| 340.50% | 159.59% | 51.90% | ||
$347m | $47m | $75m | $80m | |
| 17358.36% | 537.30% | 326.46% | 230.14% | |
$-345m | $-39m | $-52m | $-45m | |
| -17258.36% | -437.30% | -226.46% | -130.14% | |
$-346m | $-41m | $-58m | $-53m | |
| -17293.88% | -462.05% | -251.91% | -153.49% | |
| ENVIRONMENTAL COST DATA | ||||
$0m | $0m | $2m | $1m | |
| 1.19% | 0.69% | 7.07% | 3.57% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-345m | $-39m | $-53m | $-46m | |
| -17259.55% | -437.99% | -233.53% | -133.71% | |
$-346m | $-41m | $-59m | $-55m | |
| -17295.07% | -462.75% | -258.98% | -157.06% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
1.96%
Scope 2 (% of Sales)
5.11%
Operational Environmental Cost Intensity
7.07%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Ocumension Therapeutics | KY | $2m | 7.07% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022